Skip to main content
. 2022 Feb 18;2022:2203615. doi: 10.1155/2022/2203615

Figure 2.

Figure 2

The expression of DEFB1 in pancancer and OSCC. (a) The result of unpaired sample analysis investigating the mRNA levels of six defensin family genes (DEFA1, DEFA3, DEFB1,DEFB103B, DEFB4A, and DEFB114) in OSCC tissues and normal oral tissues in TCGA. (b) The result of paired sample analysis investigating the mRNA levels of six defensin family genes (DEFA1, DEFA3, DEFB1, DEFB103B, DEFB4A, and DEFB114) in OSCC tissues and normal oral tissues in TCGA. (c) The result of unpaired sample analysis investigating the mRNA levels of DEFB1 in OSCC tissues and normal oral tissues in TCGA. (d) The result of paired sample analysis investigating the mRNA levels of DEFB1 in OSCC tissues and normal oral tissues in TCGA. (e) The result of unpaired sample analysis investigating the mRNA expression level of the DEFB1 gene in different tumor types analyzed based on TCGA data. (f) The result of paired sample analysis investigating the mRNA expression level of the DEFB1 gene in different tumor types analyzed based on TCGA data. (g) The correlation between DEFB1 and four methylation sites (cg20710667, cg01691696, cg02465761, and cg24292612). (h) The association of DEFB1 mRNA expression with clinicopathological features, for example, histologic grade (p = 0.036), lymph node neck dissection (p = 0.014), alcohol history (p = 0.006), and OS event (p = 0.035).